Commonwealth Equity Services
GANX icon

Commonwealth Equity Services’s Gain Therapeutics GANX Stock Holding History

Commonwealth Equity Services’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$57.6K Buy
29,703
+17,018
+134% +$37K ﹤0.01% 4186
2025
Q4 		$40.9K Buy
+12,685
New +$33.9K ﹤0.01% 4200

Other funds holding GANX

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
PCM
Potomac Capital Management New York $115M AUM
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Commonwealth Equity Services's GANX Position: Q1 2026 in Review

Commonwealth Equity Services increased its Gain Therapeutics (GANX) stake by 134% in Q1 2026, buying an estimated $37K and bringing the position to 29,703 shares worth $57.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4186.

Commonwealth Equity Services first reported a position in GANX in Q4 2025 and has held it in 2 quarters since. 42 funds tracked by Wall St. Rank hold GANX as of Q1 2026.

  • Commonwealth Equity Services held 29,703 shares of Gain Therapeutics worth $57.6K as of Q1 2026.
  • Commonwealth Equity Services bought 17,018 Gain Therapeutics shares in Q1 2026, an estimated $37K.
  • Gain Therapeutics made up ﹤0.01% of Commonwealth Equity Services's portfolio in Q1 2026, its #4186 holding.
  • Commonwealth Equity Services first reported a position in Gain Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 42 funds tracked by Wall St. Rank held Gain Therapeutics as of Q1 2026.

Based on Commonwealth Equity Services's 13F filing for Q1 2026, filed 27 Apr 2026.